{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:52:12Z","timestamp":1790657532419,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006694","name":"Associazione Italiana Contro le Leucemie - Linfomi e Mieloma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Classical Hodgkin\u2019s lymphoma (CHL) accounts for 10% of all lymphomas. Nodular sclerosis and mixed cellularity accounts for nearly 80% of all CHL cases. The number of mast cells in CHL correlates with poor prognosis, is significantly higher in nodular sclerosis than in other CHL subtypes, and an association between the degree of angiogenesis and the number of intratumoral mast cells has been demonstrated in CHL. Even with the best available treatment, a significant percentage of CHL patients progress or relapse after first-line therapy. 50% of patients with disease relapse achieve subsequent long-term disease control with salvage therapies. In this context, new potential therapeutic opportunities are required, and mast cells may be regarded as a new target for adjuvant treatment of CHL through the inhibition of angiogenesis and tissue remodeling and allowing the secretion of cytotoxic cytokines.<\/jats:p>","DOI":"10.3389\/fonc.2022.964573","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T07:24:42Z","timestamp":1665645882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Inflammatory microenvironment in classical Hodgkin\u2019s lymphoma with special stress on mast cells"],"prefix":"10.3389","volume":"12","author":[{"given":"Domenico","family":"Ribatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Annese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2711","article-title":"The classical hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.48.2.160","article-title":"Transforming growth factor beta 1 messenger RNA in reed-sternberg cells in nodular sclerosing hodgkin's disease","volume":"48","author":"Newcom","year":"1995","journal-title":"J Clin Pathol"},{"key":"B4","article-title":"Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing hodgkin's disease","volume":"136","author":"Kadin","year":"1990","journal-title":"Am J Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2001.01083.x","article-title":"Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis","volume":"38","author":"Ohshima","year":"2001","journal-title":"Histopathology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/0394632016644447","article-title":"Role of mast cells in fibrosis of classical Hodgkin lymphoma","volume":"29","author":"Nakayama","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.prp.2007.11.005","article-title":"Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma","volume":"204","author":"Citak","year":"2008","journal-title":"Pathol - Res Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.813629","article-title":"Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-a, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma","volume":"55","author":"Dimtsas","year":"2013","journal-title":"Leukemia Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for reed-sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.951849","article-title":"High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages","volume":"56","author":"Panico","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ajh.22168","article-title":"Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma","volume":"86","author":"Thompson","year":"2011","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e87066","DOI":"10.1371\/journal.pone.0087066","article-title":"CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma","volume":"9","author":"Koh","year":"2014","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr157","article-title":"Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma","volume":"23","author":"Azambuja","year":"2012","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/his.12458","article-title":"The role of the microenvironment in human immunodeficiency virus-associated classical Hodgkin lymphoma","volume":"65","author":"Koulis","year":"2014","journal-title":"Histopathology"},{"key":"B18","first-page":"1","article-title":"Analysis of myeloid suppressor marker arginase identifies CD68+\/arginase+ myeloid\/monocytic subsets and exerts stronger prognostic influence than macrophage quantification in classical Hodgkin lymphoma","volume":"98","author":"Gallamini","year":"2013","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15801","article-title":"Immune off-target effects of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma","volume":"185","author":"Romano","year":"2019","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.316","article-title":"Do mast cells help angiogenesis in b-cell non-hodgkin\u2019s lymphomas","volume":"77","author":"Ribatti","year":"1998","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2014.02.003","article-title":"Mast cell ontogeny: An historical overview","author":"Ribatti","year":"2014","journal-title":"Immunol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.07.005","article-title":"The dual role of mast cells in tumor fate","volume":"433","author":"Ribatti","year":"2018","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/BF02893504","article-title":"Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in hodgkin\u2019s lymphoma","volume":"13","author":"Keresztes","year":"2007","journal-title":"Pathol Oncol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03768.x","article-title":"Mast cell infiltration correlates with poor prognosis in hodgkin's lymphoma","volume":"119","author":"Molin","year":"2002","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.37.5.519","article-title":"A quantitative study of mast cells in hodgkin's disease","volume":"37","author":"Crocker","year":"1984","journal-title":"J Clin Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01652.x","article-title":"Predictors of histology, tissue eosinophilia and mast cell infiltration in hodgkin\u2019s lymphoma - A population-based study","volume":"87","author":"Glimelius","year":"2011","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403992","article-title":"Angiogenesis and mast cells in Hodgkin lymphoma","volume":"19","author":"Glimelius","year":"2005","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-003-0043-3","article-title":"Mast cells in the pathogenesis of fibrosis","volume":"5","author":"Gruber","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.81","article-title":"Mast cells promote the growth of hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib","volume":"26","author":"Mizuno","year":"2012","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04190.x","article-title":"Transforming growth factor beta 1 plays an important role in inducing CD4+CD25+forhead box P3+ regulatory T cells by mast cells","volume":"161","author":"Zhang","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.03.003","article-title":"Immunotherapy in Hodgkin lymphoma: The road ahead","volume":"40","author":"Ansell","year":"2019","journal-title":"Trends Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti\u2013PD-1 antibody camrelizumab in Relapsed\/Refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01652","article-title":"Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: A Nordic lymphoma epidemiology group study","volume":"37","author":"Biccler","year":"2019","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.leukres.2003.11.002","article-title":"Clinical relevance of circulating angiogenic factors in patients with non-hodgkin\u2019s lymphoma or hodgkin\u2019s lymphoma","volume":"28","author":"Giles","year":"2004","journal-title":"Leukemia Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147033","article-title":"SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment","volume":"112","author":"Huang","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.05.023","article-title":"Insights in Hodgkin lymphoma angiogenesis","volume":"38","author":"Marinaccio","year":"2014","journal-title":"Leukemia Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.964573\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T07:24:46Z","timestamp":1665645886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.964573\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":38,"alternative-id":["10.3389\/fonc.2022.964573"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.964573","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"964573"}}